

1014. J Neurovirol. 2017 Oct;23(5):783-785. doi: 10.1007/s13365-017-0558-4. Epub 2017
Aug 8.

Fatal ruxolitinib-related JC virus meningitis.

Ballesta B(1), González H(2), Martín V(3), Ballesta JJ(4)(5).

Author information: 
(1)Intensive Care Unit, Hospital Universitario Nuestra Señora de la Candelaria,
Carretera General del Rosario 145, 38010, Santa Cruz de Tenerife, Spain.
(2)Department of Hematology, Hospital Universitario Nuestra Señora de la
Candelaria, Carretera General del Rosario 145, 38010, Santa Cruz de Tenerife,
Spain.
(3)Department of Radiology, Hospital Universitario Nuestra Señora de la
Candelaria, Carretera General del Rosario 145, 38010, Santa Cruz de Tenerife,
Spain.
(4)Alacant Institute for Health and Biomedical Research (ISABIAL - FISABIO
Foundation), Calle Pintor Baeza 12, 03010, Alacant, Spain. jj.ballesta@umh.es.
(5)Institute of Neurosciences, Universidad Miguel Hernandez-CSIC, Avenida
Santiago Ramón y Cajal s/n, Sant Joan d'Alacant, 03550, Alacant, Spain.
jj.ballesta@umh.es.

We report a possible association between ruxolitinib and JC virus meningitis. A
72-year-old man with myelofibrosis started treatment with ruxolitinib.
Fourteen days later, the patient presented to the emergency department with fever
and nausea. HIV test was negative. Ruxolitinib was suspended. Symptoms progressed
with neck stiffness, cognitive impairment, and motor aphasia. CSF was positive
for JC virus. MRI showed nonspecific abnormal findings. Five days after the
clinical debut, the patient died. The clinical picture, MRI imaging, and positive
JC virus PCR in CSF strongly suggest ruxolitinib-related JC virus meningitis.

DOI: 10.1007/s13365-017-0558-4 
PMID: 28791626  [Indexed for MEDLINE]
